Lipocine Inc.
Compositions and methods for treating central nervous system disorders

Abstract:

The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3.alpha.-OH-5.alpha.-pregnan-20-one, or 3.alpha.-OH-5.beta.-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3.alpha.-OH-5.alpha.-pregnan-20-one, or 3.alpha.-OH-5.beta.-pregnan-20-one, or both that is sufficient to treat the CNS disorder.